AXIM (AXIM Biotechnologies) PEG Ratio: 0.00 (As of Jun. 25, 2026)


What is AXIM Biotechnologies PEG Ratio?

AXIM Biotechnologies AXIM PEG Ratio is 0.00 as of Jun. 25, 2026. The stock has 7 warning signs investors should review. Among 95 Biotechnology companies, AXIM Biotechnologies ranks worse than 1052630.53% on this metric.

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, AXIM Biotechnologies's PE Ratio without NRI is 0.00. AXIM Biotechnologies's 5-Year EBITDA growth rate is 29.10%. Therefore, AXIM Biotechnologies's PEG Ratio for today is 0.00.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for AXIM Biotechnologies's PEG Ratio or its related term are showing as below:



AXIM's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.93
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


AXIM Biotechnologies  (OTCPK:AXIM) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


AXIM Biotechnologies PEG Ratio Related Terms


AXIM Biotechnologies PEG Ratio Historical Data

* Premium members only.

The historical data trend for AXIM Biotechnologies's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AXIM Biotechnologies PEG Ratio Chart

AXIM Biotechnologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AXIM Biotechnologies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AXIM vs HEPA, SCNI, BZYR: PEG Ratio Comparison

For the Biotechnology subindustry, AXIM Biotechnologies's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AXIM Biotechnologies PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's PEG Ratio distribution charts can be found below:

* The bar in red indicates where AXIM Biotechnologies's PEG Ratio falls into.



AXIM Biotechnologies PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

AXIM Biotechnologies's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/29.10
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Frequently Asked Questions Learn more about PEG Ratio →
What does a PEG Ratio of 0.00 mean?
AXIM Biotechnologies (AXIM) has a PEG Ratio of 0.00 as of Jun. 25, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on AXIM Biotechnologies and its competitors. According to the industry distribution chart, AXIM Biotechnologies ranks #999999 out of 95 companies in the Biotechnology industry.
Is AXIM Biotechnologies' PEG Ratio too high?
AXIM Biotechnologies' current PEG Ratio is 0.00. Based on the distribution chart, AXIM Biotechnologies ranks #999999 out of 95 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does AXIM Biotechnologies' PEG Ratio compare to HEPA and SCNI?
According to the Biotechnology industry distribution chart, AXIM Biotechnologies ranks #999999 out of 95 companies for PEG Ratio. This places AXIM Biotechnologies in the lower half of its industry. The industry median PEG Ratio is 1.93. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.93, based on 95 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on AXIM Biotechnologies and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AXIM Biotechnologies's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AXIM Biotechnologies stock overvalued right now?
AXIM Biotechnologies (AXIM) has a current PEG Ratio of 0.00. The current PEG Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For AXIM Biotechnologies (AXIM), the current PEG Ratio is 0.00 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AXIM Biotechnologies Business Description

Address 6048 Cornerstone Court West, Suite E1, San Diego, CA, USA, 92121
AXIM Biotechnologies Inc is a integrated research and development company and developer of diagnostic healthcare solutions serving to enhance the health of people. The company focuses on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.